XML 68 R47.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segments of Business and Geographic Areas (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2017
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information |
|  | Sales to Customers
(Dollars in Millions) |  | 2017 |  | 2016 |  | 2015
Consumer — |  |  |  |  |  |
United States |  | $ | 5,565 |  |  | 5,420 |  |  | 5,222 |
International |  | 8,037 |  |  | 7,887 |  |  | 8,285 |
Total |  | 13,602 |  |  | 13,307 |  |  | 13,507 |
Pharmaceutical — |  |  |  |  |  |
United States |  | 21,474 |  |  | 20,125 |  |  | 18,333 |
International |  | 14,782 |  |  | 13,339 |  |  | 13,097 |
Total |  | 36,256 |  |  | 33,464 |  |  | 31,430 |
Medical Devices — |  |  |  |  |  |
United States |  | 12,824 |  |  | 12,266 |  |  | 12,132 |
International |  | 13,768 |  |  | 12,853 |  |  | 13,005 |
Total |  | 26,592 |  |  | 25,119 |  |  | 25,137 |
Worldwide total |  | $ | 76,450 |  |  | 71,890 |  |  | 70,074 |
|  | Income Before Tax |  | Identifiable Assets
(Dollars in Millions) |  | 2017 (3) |  | 2016 (4) |  | 2015 (5) |  | 2017 |  | 2016
Consumer |  | $ | 2,524 |  |  | 2,441 |  |  | 1,787 |  |  | $ | 25,030 |  |  | 23,971 |
Pharmaceutical |  | 11,083 |  |  | 12,827 |  |  | 11,734 |  |  | 59,450 |  |  | 27,477 |
Medical Devices |  | 5,392 |  |  | 5,578 |  |  | 6,826 |  |  | 45,413 |  |  | 39,773 |
Total |  | 18,999 |  |  | 20,846 |  |  | 20,347 |  |  | 129,893 |  |  | 91,221 |
Less: Expense not allocated to segments (1) |  | 1,326 |  |  | 1,043 |  |  | 1,151 |  |  |  |  |
General corporate (2) |  |  |  |  |  |  |  | 27,410 |  |  | 49,987 |
Worldwide total |  | $ | 17,673 |  |  | 19,803 |  |  | 19,196 |  |  | $ | 157,303 |  |  | 141,208 |
|  | Additions to Property, Plant & Equipment |  | Depreciation and Amortization
(Dollars in Millions) |  | 2017 |  | 2016 |  | 2015 |  | 2017 |  | 2016 |  | 2015
Consumer |  | $ | 485 |  |  | 486 |  |  | 544 |  |  | $ | 674 |  |  | 608 |  |  | 559 |
Pharmaceutical |  | 936 |  |  | 927 |  |  | 1,063 |  |  | 2,416 |  |  | 886 |  |  | 929 |
Medical Devices |  | 1,566 |  |  | 1,472 |  |  | 1,631 |  |  | 2,216 |  |  | 1,928 |  |  | 1,945 |
Segments total |  | 2,987 |  |  | 2,885 |  |  | 3,238 |  |  | 5,306 |  |  | 3,422 |  |  | 3,433 |
General corporate |  | 292 |  |  | 341 |  |  | 225 |  |  | 336 |  |  | 332 |  |  | 313 |
Worldwide total |  | $ | 3,279 |  |  | 3,226 |  |  | 3,463 |  |  | $ | 5,642 |  |  | 3,754 |  |  | 3,746 |
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas |
|  | Sales to Customers |  | Long-Lived Assets (6)
(Dollars in Millions) |  | 2017 |  | 2016 |  | 2015 |  | 2017 |  | 2016
United States |  | $ | 39,863 |  |  | 37,811 |  |  | 35,687 |  |  | $ | 38,556 |  |  | 36,934 |
Europe |  | 17,126 |  |  | 15,770 |  |  | 15,995 |  |  | 56,677 |  |  | 21,996 |
Western Hemisphere excluding U.S. |  | 6,041 |  |  | 5,734 |  |  | 6,045 |  |  | 2,990 |  |  | 2,961 |
Asia-Pacific, Africa |  | 13,420 |  |  | 12,575 |  |  | 12,347 |  |  | 2,773 |  |  | 2,512 |
Segments total |  | 76,450 |  |  | 71,890 |  |  | 70,074 |  |  | 100,996 |  |  | 64,403 |
General corporate |  |  |  |  |  |  |  | 1,143 |  |  | 1,190 |
Other non long-lived assets |  |  |  |  |  |  |  | 55,164 |  |  | 75,615 |
Worldwide total |  | $ | 76,450 |  |  | 71,890 |  |  | 70,074 |  |  | $ | 157,303 |  |  | 141,208 |
See Note 1 for a description of the segments in which the Company operates. Export sales are not significant. In 2017, the Company had two wholesalers distributing products for all three segments that represented approximately 14.0% and 10.0% of the total consolidated revenues. In 2016, the Company had two wholesalers distributing products for all three segments that represented approximately 13.5% and 10.7% of the total consolidated revenues. In 2015, the Company had one wholesaler distributing products for all three segments that represented approximately 12.5% of the total consolidated revenues.
(1) | Amounts not allocated to segments include interest (income) expense and general corporate (income) expense.
(2) | General corporate includes cash, cash equivalents and marketable securities.
(3) | The Pharmaceutical segment includes $797 million for Actelion acquisition related costs, an in-process research and development expense of $396 million and net litigation expense of $117 million. The Medical Devices segment includes net litigation expense of $1,139 million, a restructuring related charge of $760 million, an asset impairment of $215 million primarily related to the insulin pump business and $140 million for AMO acquisition related costs. The Medical Devices segment includes a gain of $0.7 billion from the divestiture of Codman Neurosurgery. The Consumer segment includes a gain of $0.5 billion from the divestiture of COMPEED®.
(4) | Includes net litigation expense of $806 million and a restructuring related charge of $685 million in the Medical Devices segment. The Pharmaceutical segment includes a positive adjustment of $0.5 billion to previous reserve estimates, an in-process research and development expense of $29 million, and gains from the divestitures of the controlled substance raw material and active pharmaceutical ingredient (API) business and certain anesthetic products in Europe.
(5) | The Medical Devices segment includes a restructuring related charge of $590 million, an intangible asset write-down of $346 million related to Acclarent, Synthes integration costs of $196 million and $148 million expense for the cost associated with the DePuy ASR TM Hip program. Includes $224 million of in-process research and development expense, comprised of $214 million and $10 million in the Pharmaceutical and Medical Devices segments, respectively. Includes net litigation expense of $141 million comprised of $136 million in the Pharmaceutical segment and $5 million in the Medical Devices segment, which included the gain from the litigation settlement agreement with Guidant for $600 million. The Medical Devices Segment includes a gain of $1.3 billion from the divestiture of the Cordis business. The Pharmaceutical segment includes a gain of $981 million from the U.S. divestiture of NUCYNTA® and a positive adjustment of $0.5 billion to previous reserve estimates, including Managed Medicaid rebates. The Consumer segment includes a gain of $229 million from the divestiture of SPLENDA® brand.
(6) | Long-lived assets include property, plant and equipment, net for 2017, and 2016 of $17,005 and $15,912, respectively, and intangible assets and goodwill, net for 2017 and 2016 of $85,134 and $49,681, respectively.

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8813-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8736-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration